Arcus reports Q2 2024 net loss $93M, cash $1.0B; casdatifan data due Q4

Arcus Biosciences, Inc.

2024-Q2 EPS reported -$1.09 revenue$184,000,000

Revenue $39M (up from $29M in Q2 2023); net loss $93M vs $75M year-over-year.
Cash, cash equivalents and marketable securities $1.0B, sufficient into 2027; expects $885-925M by year-end 2024.
Casdatifan 100mg ccRCC expansion ORR data expected Q4 2024; PEAK-1 Phase 3 study start H1 2025.
STAR-221 (domvanalimab+chemo) completed enrollment; STAR-121 (NSCLC) expected to complete enrollment in 2024.
Taiho exercised option for quemliclustat in Japan/Asia; Phase 3 PRISM-1 pancreatic cancer to start early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.